Literature DB >> 30851232

Experimental models to unravel the molecular pathogenesis, cell of origin and stem cell properties of cholangiocarcinoma.

Silvestre Vicent1,2,3, Ruby Lieshout4, Anna Saborowski5, Monique M A Verstegen4, Chiara Raggi6,7, Stefania Recalcati8, Pietro Invernizzi9, Luc J W van der Laan4, Domenico Alvaro10, Diego F Calvisi11, Vincenzo Cardinale12.   

Abstract

Human cholangiocarcinoma (CCA) is an aggressive tumour entity arising from the biliary tree, whose molecular pathogenesis remains largely undeciphered. Over the last decade, the advent of high-throughput and cell-based techniques has significantly increased our knowledge on the molecular mechanisms underlying this disease while, at the same time, unravelling CCA complexity. In particular, it becomes clear that CCA displays pronounced inter- and intratumoural heterogeneity, which is presumably the consequence of the interplay between distinct tissues and cells of origin, the underlying diseases, and the associated molecular alterations. To better characterize these events and to design novel and more effective therapeutic strategies, a number of CCA experimental and preclinical models have been developed and are currently generated. This review summarizes the current knowledge and understanding of these models, critically underlining their translational usefulness and limitations. Furthermore, this review aims to provide a comprehensive overview on cells of origin, cancers stem cells and their dynamic interplay within CCA tissue.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  cancer stem cells; cholangiocarcinoma; in vitro and in vivo models; tumour cells of origin

Mesh:

Year:  2019        PMID: 30851232     DOI: 10.1111/liv.14094

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  16 in total

Review 1.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

2.  3D Silk Fibroin-Gelatin/Hyaluronic Acid/Heparan Sulfate Scaffold Enhances Expression of Stemness and EMT Markers in Cholangiocarcinoma.

Authors:  Onanong Buhome; Molin Wongwattanakul; Jureerut Daduang; Temduang Limpaiboon
Journal:  In Vivo       Date:  2022 May-Jun       Impact factor: 2.406

Review 3.  Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression.

Authors:  Alphonse E Sirica; Mario Strazzabosco; Massimiliano Cadamuro
Journal:  Adv Cancer Res       Date:  2020-12-09       Impact factor: 6.242

Review 4.  Functions and the Emerging Role of the Foetal Liver into Regenerative Medicine.

Authors:  Antonella Giancotti; Marco Monti; Lorenzo Nevi; Samira Safarikia; Valentina D’Ambrosio; Roberto Brunelli; Cristina Pajno; Sara Corno; Violante Di Donato; Angela Musella; Michele Francesco Chiappetta; Daniela Bosco; Pierluigi Benedetti Panici; Domenico Alvaro; Vincenzo Cardinale
Journal:  Cells       Date:  2019-08-16       Impact factor: 6.600

Review 5.  Recreating Tumour Complexity in a Dish: Organoid Models to Study Liver Cancer Cells and their Extracellular Environment.

Authors:  Gilles S van Tienderen; Bas Groot Koerkamp; Jan N M IJzermans; Luc J W van der Laan; Monique M A Verstegen
Journal:  Cancers (Basel)       Date:  2019-11-01       Impact factor: 6.639

Review 6.  Co-Clinical Trials: An Innovative Drug Development Platform for Cholangiocarcinoma.

Authors:  Brinda Balasubramanian; Simran Venkatraman; Kyaw Zwar Myint; Tavan Janvilisri; Kanokpan Wongprasert; Supeecha Kumkate; David O Bates; Rutaiwan Tohtong
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-11

Review 7.  Cholangiocarcinoma: bridging the translational gap from preclinical to clinical development and implications for future therapy.

Authors:  Leonardo Baiocchi; Keisaku Sato; Burcin Ekser; Lindsey Kennedy; Heather Francis; Ludovica Ceci; Ilaria Lenci; Domenico Alvaro; Antonio Franchitto; Paolo Onori; Eugenio Gaudio; Chaodong Wu; Sanjukta Chakraborty; Shannon Glaser; Gianfranco Alpini
Journal:  Expert Opin Investig Drugs       Date:  2020-12-08       Impact factor: 6.206

8.  Somatic mutation landscape reveals differential variability of cell-of-origin for primary liver cancer.

Authors:  Kyungsik Ha; Masashi Fujita; Rosa Karlić; Sungmin Yang; Ruidong Xue; Chong Zhang; Fan Bai; Ning Zhang; Yujin Hoshida; Paz Polak; Hidewaki Nakagawa; Hong-Gee Kim; Hwajin Lee
Journal:  Heliyon       Date:  2020-02-11

9.  Mitochondrial Fusion Via OPA1 and MFN1 Supports Liver Tumor Cell Metabolism and Growth.

Authors:  Meng Li; Ling Wang; Yijin Wang; Shaoshi Zhang; Guoying Zhou; Ruby Lieshout; Buyun Ma; Jiaye Liu; Changbo Qu; Monique M A Verstegen; Dave Sprengers; Jaap Kwekkeboom; Luc J W van der Laan; Wanlu Cao; Maikel P Peppelenbosch; Qiuwei Pan
Journal:  Cells       Date:  2020-01-04       Impact factor: 6.600

10.  Genomic characterization of co-existing neoplasia and carcinoma lesions reveals distinct evolutionary paths of gallbladder cancer.

Authors:  Jianzhen Lin; Xinxin Peng; Kun Dong; Junyu Long; Xuejiao Guo; Hongyue Li; Yi Bai; Xu Yang; Dongxu Wang; Xin Lu; Yilei Mao; Xinting Sang; Xuwo Ji; Haitao Zhao; Han Liang
Journal:  Nat Commun       Date:  2021-08-06       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.